

ASX Release

16 January 2025

Launch of 90 gram presentation of Dapsone 5%, Gel in the United States

Melbourne, Australia; Acrux Limited (ASX:ACR)

Acrux and its partner TruPharma today announced the launch of a 90 gram pack size of Dapsone 5%, Gel in the United States.

Dapsone 5%, Gel is a topical prescription medicine to treat acne vulgaris.

Annual market sales for Dapsone 5%, Gel products for the 12 months ending August 2024 exceeded US\$15.8 million (AUD\$24 million) as measured by IQVIA.



CEO and Managing Director of Acrux, Michael Kotsanis, said:

"While the market for the 90 gram pack size represents only 16% of volume for the product, the offering of both pack sizes will improve the product's competitive profile and we anticipate a positive impact on market share for the product following this launch."

Authorised for release by the Board of Acrux Limited.

For more information, please contact: Michael Kotsanis Acrux Limited CEO & Managing Director P: + 61 3 8379 0100 E: michael.kotsanis@acrux.com.au



About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au

About TruPharma

TruPharma, LLC is a front-end pharma sales and marketing company focused on commercializing branded and generic prescription drugs for the U.S. Market. TruPharma has a diverse portfolio of products distributed across multiple channels. TruPharma is operated by a team of experienced executives focused on getting complex products FDA-approved and into the market. For more Information: www.trupharma.com